Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer.

Background: Patients with advanced pancreatic carcinoma have a risk of relapse after primary therapy, and the prognosis for these patients remains bleak. The effect of immuno-cell therapy in advanced pancreatic carcinoma, with or without other standard therapies, was examined.

Patients And Methods: Forty-six patients with advanced pancreatic carcinoma, undergoing immuno-cell treatment, were evaluated.

A report of three patients treated with immunocell therapy with imatinib mesylate.

Background: Immunocell therapy has been applied to patients with refractory cancer in clinical trials or as an unconventional cancer therapy, however the efficacy is still limited. To improve this efficacy, a combination therapy may be beneficial. Molecularly-targeted therapy acts directly on neoplasm cells to suppress their growth without causing myelosuppression.